depression | CARLAT PUBLISHING

Clinical Update

Breaking the Silence: Addressing the Hidden Crisis of Elder Abuse

February 17, 2025

Rehan Aziz, MD. Program director, geriatric psychiatry fellowship program, Jersey Shore University Medical Center, Neptune, NJ; associate professor of psychiatry and neurology at Hackensack Meridian School of Medicine, Nutley, NJ.

Dr. Aziz has no financial relationships with companies related to this material.

Dr. Aziz sheds light on the hidden crisis of elder abuse, exploring its physical, emotional, and financial forms. Learn how to recognize warning signs, support vulnerable adults, and take action to break the cycle of neglect and mistreatment in older adults.

Clinical Update

How Long Should We Continue Esketamine?

February 1, 2025

Steven Hamilton, PhD, MD

Steven Hamilton, MD, PhD. The Permanente Medical Group, Department of Psychiatry, Kaiser Permanente San Francisco Medical Center.

Dr. Hamilton has no financial relationships with companies related to this material.

Response to esketamine (Spravato) is brisk and bold, but how do you keep patients well over the long term? We look at new research on continuation, tapering, and switching strategies.

Expert Q&A

ADHD: Beyond Stimulants

January 1, 2025

Nicholas J. Nissen, MD

Nicholas J. Nissen, MD

Concierge psychiatrist, specializing in nonstimulant management of ADHD and anxiety disorders. Austin, TX.

Dr. Nissen has no financial relationships with companies related to this material.

Stimulants may hold the prize for effect size in ADHD, but nonstimulants have advantages for the right patient. Nicholas Nissen shows us how to use five medications, two supplements, and lifestyle approaches in ADHD.

Chronic Depression with Allen Frances

December 30, 2024

Kellie Newsome, PMHNP, Allen Frances, MD, and Chris Aiken, MD

Allen Frances shares his approach to chronic depression.

Research Update

Esketamine vs Quetiapine in Treatment-Resistant Depression

November 1, 2024

Ivy Song, MD

Ivy Song, MD. Dr. Song has no financial relationships with companies related to this material.

Esketamine outperforms quetiapine in TRD remission rates, but the clinical significance of this difference remains uncertain.

Expert Q&A

How to Stop a Psychiatric Med

November 1, 2024

Mark Horowitz, MBBS, PhD

Mark Horowitz, MBBS, PhD

Research and Development Department, Goodmayes Hospital, North East London NHS Foundation Trust, Essex, UK; Visiting Lecturer in Psychopharmcology, King’s College London. Co-author of The Maudsley Deprescribing Guidelines (Wiley-Blackwell; 2024).

Dr. Horowitz is cofounder and consultant for Outro Health. Dr. Aiken has reviewed this educational activity and has determined that there is no commercial bias as a result of this financial relationship.

Dr. Horowitz explains the principle, practicalities, and science of tapering psychiatric medications.

Research Update

High-Dose Aspirin and Age Are the Only Convincing Depression Risk Factors in Late Life

October 1, 2024

Kathryn Kieran, MSN, PMHNP-BC

Kathryn Kieran, MSN, PMHNP-BC. Ms. Kieran has no financial relationships with companies related to this material.

This umbrella review looked at modifiable risk factors for late life depression—and only two stood out.

Clinical Update

Unraveling Post-SSRI Sexual Dysfunction

September 26, 2024

Awais Aftab, MD.

Awais Aftab, MD. Psychiatrist in Cleveland, Ohio, and Clinical Assistant Professor of Psychiatry at Case Western Reserve University. Author of the online newsletter Psychiatry at the Margins.

Dr. Aftab has no financial relationships with companies related to this material.

Patient advocacy groups are adamant that it exists. European regulators have given it the stamp of approval. Here, we look at the evidence that sexual dysfunction can persist long after stopping an SSRI.

L-Methylfolate May Offer Modest Boost to Antidepressants

September 4, 2024

Greg Malzberg, MD and Glen Spielmans, PhD.

In this video, we explore the potential of L-Methylfolate as a vital supplement in depression treatment. L-Methylfolate is a form of folate, a naturally occurring B-vitamin, and is often used to enhance the effects of traditional antidepressants.

Expert Q&A

Looking Back on Prozac

September 3, 2024

Peter D. Kramer, MD

Peter D. Kramer, MD

Emeritus Professor of Psychiatry and Human Behavior, Brown University. Author of eight books, including the runaway bestseller Listening to Prozac (Viking Adult, 1993) and Death of the Great Man (Post Hill Press, 2023).

Dr. Kramer has no financial relationships with companies related to this material.

Dr. Kramer examines how certain antidepressants can alter personality traits, while also exploring the ethical concerns and long-term effects of these changes.